Literature DB >> 6091874

Monoclonal antibodies to surface antigens of small cell carcinoma of the lung.

T Okabe, T Kaizu, M Fujisawa, J Watanabe, K Kojima, T Yamashita, F Takaku.   

Abstract

Monoclonal antibodies to membrane antigens of human small cell carcinoma of the lung were produced by fusion of P3X63/Ag8U1 mouse myeloma cells with spleen cells from BALB/c mice immunized against the intact cells of the small cell carcinomas grown in BALB/c nude mice. The hybrids were screened for antibody production using intact cells in a solid-phase radioimmunoassay or in a membrane fluorescence with a fluorescence-activated cell sorter. Four monoclonal antibodies were chosen that demonstrated reactivities with human small cell carcinoma of the lung and not with apparently normal diploid fibroblasts or lymphoblastoid cells. The antibodies designated as TFS-1 and TFS-2 rather demonstrated "pancarcinoma" reactivity, showing binding to the other types of lung cancer (adenocarcinoma, squamous cell carcinoma, and large cell carcinoma) and carcinomas derived from other organs, such as colon, pancreas, or stomach. The monoclonal antibodies TFS-3 and TFS-4 preferentially bound to small cell carcinoma cells and neuroblastoma cells, but not to non-small cell carcinomas (adenocarcinoma, squamous cell, or large cell). Especially, TFS-4 did not bind to a variety of other normal or malignant cells. Immunoprecipitation of the antigens by monoclonal antibodies and sodium dodecyl sulfate:polyacrylamide gel electrophoresis revealed that they had different molecular weights.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6091874

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  8 in total

1.  Evolution, expression, and chromosomal location of a novel receptor tyrosine kinase gene, eph.

Authors:  Y Maru; H Hirai; M C Yoshida; F Takaku
Journal:  Mol Cell Biol       Date:  1988-09       Impact factor: 4.272

2.  Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity.

Authors:  D B Axworthy; J M Reno; M D Hylarides; R W Mallett; L J Theodore; L M Gustavson; F Su; L J Hobson; P L Beaumier; A R Fritzberg
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-15       Impact factor: 11.205

3.  Detection of bone marrow metastases in small cell lung cancer patients. Comparison of immunologic and morphologic methods.

Authors:  K Beiske; A T Myklebust; S Aamdal; R Langholm; E Jakobsen; O Fodstad
Journal:  Am J Pathol       Date:  1992-09       Impact factor: 4.307

4.  Radioimmunotherapy of transplanted small cell lung cancer with 131I-labelled monoclonal antibody.

Authors:  S Yoneda; M Fujisawa; J Watanabe; T Okabe; F Takaku; T Homma; K Yoshida
Journal:  Br J Cancer       Date:  1988-09       Impact factor: 7.640

5.  Epithelium-specific surface glycoprotein of Mr 34,000 is a widely distributed human carcinoma marker.

Authors:  G Moldenhauer; F Momburg; P Möller; R Schwartz; G J Hämmerling
Journal:  Br J Cancer       Date:  1987-12       Impact factor: 7.640

6.  Quantitative distribution of cluster 1 small cell lung cancer antigen in cancerous and non-cancerous tissues, cultured cells and sera.

Authors:  T Hirano; S Hirohashi; T Kunii; M Noguchi; Y Shimosato; Y Hayata
Journal:  Jpn J Cancer Res       Date:  1989-04

7.  Effective removal of SCLC cells from human bone marrow. Use of four monoclonal antibodies and immunomagnetic beads.

Authors:  A T Myklebust; A Pharo; O Fodstad
Journal:  Br J Cancer       Date:  1993-06       Impact factor: 7.640

8.  Isolation of a cDNA for a growth factor of vascular endothelial cells from human lung cancer cells: its identity with insulin-like growth factor II.

Authors:  K Hagiwara; T Kobayashi; M Tobita; N Kikyo; Y Yazaki; T Okabe
Journal:  Jpn J Cancer Res       Date:  1995-02
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.